PMID- 23386902
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130207
LR  - 20231106
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 4
IP  - 1
DP  - 2013
TI  - Clinical relevance of natural killer cells following hematopoietic stem cell 
      transplantation.
PG  - 25-35
LID - 10.7150/jca.5049 [doi]
AB  - Natural killer (NK) cells are one of the first cells to recover following 
      allogeneic hematopoietic stem cell transplantation (HSCT), and are believed to 
      play an important role in facilitating engraftment or preventing post-transplant 
      infection and tumor recurrence. Recent studies have provided novel insights into 
      the mechanisms by which NK cells mediate these highly clinically relevant 
      immunological functions. In particular, the ability of NK cells to reduce the 
      risk of graft versus host disease (GVHD) and increase the graft versus leukemia 
      effect (GVL) in the setting of human leukocyte antigen (HLA)-haploidentical HSCT 
      highlights their clinical potentials. NK cells also mediate anti-viral 
      protection, in particular against cytomegalovirus (CMV), an infection that causes 
      significant morbidity and mortality following transplant. Another crucial 
      function of NK cells is providing protection against bacterial infections at the 
      mucosal barriers. NK cells achieve this by promoting anti-microbial defenses and 
      regeneration of epithelial cells. These recent exciting findings provide a strong 
      basis for the formulation of novel NK cell-based immunotherapies. In this review, 
      we summarize the recent advances related to the mechanisms, functions, and future 
      clinical prospects of NK cells that can impact post-transplant outcomes.
FAU - Palmer, Jeanne M
AU  - Palmer JM
AD  - 1. Laboratory of Molecular Immunology, Blood Research Institute, 8727 Watertown 
      Plank Road, Milwaukee, WI 53226, USA; ; 2. Departments of Medicine, Medical 
      College of Wisconsin, Milwaukee, WI 53226, USA;
FAU - Rajasekaran, Kamalakannan
AU  - Rajasekaran K
FAU - Thakar, Monica S
AU  - Thakar MS
FAU - Malarkannan, Subramaniam
AU  - Malarkannan S
LA  - eng
GR  - R01 AI102893/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20121205
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC3564244
OTO - NOTNLM
OT  - Natural killer cells
OT  - immunological functions
OT  - post-transplant
OT  - stem cell
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2013/02/07 06:00
MHDA- 2013/02/07 06:01
PMCR- 2013/01/01
CRDT- 2013/02/07 06:00
PHST- 2012/10/23 00:00 [received]
PHST- 2012/12/01 00:00 [accepted]
PHST- 2013/02/07 06:00 [entrez]
PHST- 2013/02/07 06:00 [pubmed]
PHST- 2013/02/07 06:01 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - jcav04p0025 [pii]
AID - 10.7150/jca.5049 [doi]
PST - ppublish
SO  - J Cancer. 2013;4(1):25-35. doi: 10.7150/jca.5049. Epub 2012 Dec 5.